Sagimet Biosciences (SGMT) Total Non-Current Liabilities (2022 - 2023)
Sagimet Biosciences (SGMT) recorded quarterly Total Non-Current Liabilities of $5.0 million in Q3 2023, down 4.5% quarter-over-quarter from $5.3 million in Q2 2023.
Sagimet Biosciences (SGMT) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2023.
- In Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $5.0 million; the TTM figure through Sep 2023 stood at $5.0 million (changed N/A YoY), while the FY2022 annual figure was $5.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $5.0 million for Q3 2023 at Sagimet Biosciences, down from $5.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $5.4 million in Q4 2022 to a low of $5.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Sagimet Biosciences | 211.96 Mn | 211.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Dec 31, 2022 | 5.36 Mn |